Catalyst Pharmaceuticals (CPRX) Enterprise Value (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Enterprise Value of -$755.9 million for Q1 2026, down 6.58% on a QoQ basis from -$709.2 million in Q4 2025, and down 30.17% year-over-year from -$1.1 billion in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Enterprise Value (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$755.9 million for Q1 2026.
- Quarterly Enterprise Value fell 30.17% year-over-year to -$755.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$755.9 million (down 30.17% YoY) and the FY2025 annual result came in at -$709.2 million, down 37.02% from the prior year.
- Enterprise Value was -$755.9 million for Q1 2026 at Catalyst Pharmaceuticals, down from -$709.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$121.0 million in Q3 2023 and bottomed at -$755.9 million in Q1 2026.
- A 5-year average of -$387.8 million and a median of -$310.4 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value soared 53.87% — and 2024, when it plunged 276.03%.
- Catalyst Pharmaceuticals' Enterprise Value stood at -$298.4 million in 2022, then surged by 53.87% to -$137.6 million in 2023, then plunged by 276.03% to -$517.6 million in 2024, then tumbled by 37.02% to -$709.2 million in 2025, then retreated by 6.58% to -$755.9 million in 2026.
- Business Quant data shows CPRX's Enterprise Value at -$755.9 million in Q1 2026, -$709.2 million in Q4 2025, and -$689.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | -755.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -755.86 Mn |
| Dec 31, 2025 | -709.17 Mn |
| Sep 30, 2025 | -689.89 Mn |
| Jun 30, 2025 | -652.80 Mn |
| Mar 31, 2025 | -580.66 Mn |
| Dec 31, 2024 | -517.55 Mn |
| Sep 30, 2024 | -442.33 Mn |
| Jun 30, 2024 | -375.69 Mn |
| Mar 31, 2024 | -310.41 Mn |
| Dec 31, 2023 | -137.64 Mn |
| Sep 30, 2023 | -120.97 Mn |
| Jun 30, 2023 | -178.79 Mn |
| Mar 31, 2023 | -148.25 Mn |
| Dec 31, 2022 | -298.40 Mn |
| Sep 30, 2022 | -256.07 Mn |
| Jun 30, 2022 | -220.79 Mn |
| Mar 31, 2022 | -197.80 Mn |
| Dec 31, 2021 | -191.27 Mn |
| Sep 30, 2021 | -174.79 Mn |
| Jun 30, 2021 | -155.28 Mn |